

## Katie Kazem

Partner



kkazem@cooley.com

+1 703 456 8043

Reston

Mergers and Acquisitions

Capital Markets

CooleyREG

France

Katie Kazem's practice focuses on corporate and securities law and includes the general representation of both public and private companies, with particular experience in advising European life sciences companies on IPOs, capital raising, SEC compliance and corporate governance. She has experience working on M&A, public offerings and venture capital financings.

### Representative company-side and underwriter-side public offerings:

- Valneva SE – \$107.6 million IPO, \$102.0 million follow-on offering
- Nanobiotix SA – \$113.3 million IPO
- Genfit SA - \$155.4 million IPO
- Innate Pharma SA - \$79.1 million IPO
- MaxCyte, Inc. - \$201.8 million IPO
- Renalytix plc - \$74.3 million IPO
- Landos Biopharma – \$100 million IPO
- 2U – \$119.3 million IPO
- Aclaris Therapeutics – \$105 million follow-on offering
- Autolus Therapeutics – \$150 million IPO
- Biohaven Pharmaceuticals - \$193.5 million IPO
- Clearside – aggregate \$77.4 million IPO and follow-on offering
- Entasis Therapeutics – \$75 million IPO
- Erytech – \$125 million IPO

## Education

George Mason University, Antonin Scalia Law School  
JD, magna cum laude, 2010

George Mason University, School of Public Policy  
MA, 2007

College of William & Mary

BA, Government, Monroe Scholar, 2003

## Admissions & Credentials

Virginia

District of Columbia